Immunotech Biopharm Ltd Reports Improved Financials and Clinical Trial Progress

Immunotech Biopharm Ltd ( (HK:6978) ) has issued an update.

Immunotech Biopharm Ltd announced its annual results for the year ended December 31, 2024, highlighting significant financial improvements. The company reported a substantial increase in other income and a notable decrease in losses before tax and total comprehensive expenses. Additionally, research and development, as well as administrative expenses, saw reductions. On the business front, the company made progress in its clinical trials, with EAL® receiving priority review in China and the conditional NDA being accepted. The 6B11-OCIK Injection completed Phase I trials, with plans to proceed to Phase II. These developments indicate a positive trajectory for the company’s operations and potential growth in the biopharmaceutical sector.

More about Immunotech Biopharm Ltd

Immunotech Biopharm Ltd is a company in the biopharmaceutical industry, focusing on the development of cellular immunotherapy products. Their primary products include EAL®, a broad-spectrum anti-tumor cellular immunotherapy product, and 6B11-OCIK Injection, an ovarian cancer treatment. The company is engaged in clinical trials and aims to advance its products through regulatory approvals.

YTD Price Performance: 60.43%

Average Trading Volume: 770,000

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.9B

Learn more about 6978 stock on TipRanks’ Stock Analysis page.